This is a very shrewd move by GC to benefit both companies. If the covid-19 test kits end up being approved by FDA, it will obviously be a huge boost to Todos as expected. In conjunction, Emerald will be introduced to the broader investors and will give the company credibility as it transitions from a CBD focused company into a biopharma. Brilliant!